Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19

patients will receive the placebo treatment in addition to Standard of Care

patients will be tested for SARS-CoV-2 on days 1, 14 and 28

patients will undergo a physical examination on days 1-14 and day 28

patient's vital signs will be measured on days 1-14 and day 28

patients will provide a blood sample for a hematology blood test on days 1-14 and day 28

patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28

patient's NEWS score will be evaluated on days 1-14 and day 28

PK test will be performed on day 1 only (only in Brazil sites)

patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28

patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28

patient's VAS scale will be evaluated on days 1-14, day 21, and day 28

patients will provide a urine sample for a urine pregnancy test on days 1, and day 28

patients will undergo an ECG examination on days 1, and day 28

patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28

patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care

patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care